section name header

Indications

High Alert

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: BRADYCARDIA, QT interval prolongation, TORSADES DE POINTES.

Derm: rash, photosensitivity.

Endo: hyperglycemia.

F and E: hypophosphatemia.

GI: appetite, lipase, liver enzymes, abdominal pain, constipation, diarrhea, esophagitis/reflux/dysphagia, nausea, vomiting, HEPATOTOXICITY, PANCREATITIS.

GU: serum creatinine.

Hemat: anemia.

Neuro: fatigue.

Resp: INTERSTITIAL LUNG DISEASE/PNEUMONITIS.

Interactions

Drug-Drug:

Drug-Natural Products:

Drug-Food:

Availability

Route/Dosage

Hepatic Impairment

US Brand Names

Zykadia

Action

Therapeutic Effects:

Classifications

Therapeutic Classification: antineoplastics

Pharmacologic Classification: kinase inhibitors

Pharmacokinetics

Absorption: Absorption follows oral administration; food significantly absorption and may risk of adverse reactions.

Distribution: Slight preference to distribute from plasma into red blood cells.

Metabolism/Excretion: Metabolized in the liver (mostly by CYP3A) and is a substrate of P-glycoprotein (P-gp); 68% eliminated unchanged in feces, 1.3% in urine.

Half-life: 41 hr.

Time/Action Profile

(clinical response)

ROUTEONSETPEAKDURATION
POunknown4–6 hr (blood level)7.1–7.4 mo

Patient/Family Teaching

Pronunciation

se-RI-ti-nib